Neurocrine Biosciences Shares Rise 13% Following Q3 Earnings Beat and Raised Guidance
Neurocrine Biosciences (NBIX) saw its stock price surge by over 13% on Tuesday following the release of third-quarter financial results that exceeded analyst expectations. The company's positive performance was further bolstered by an upward revision of its full-year sales guidance. The stock closed at $164.90, marking a daily increase of $19.55 per share. This significant jump reflects investor confidence in the neuroscience-focused biopharmaceutical firm's current growth trajectory and revenue outlook.
Tickers: $NBIX